Medical News

RSS

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

AstraZeneca and Targacept, Inc., today announced the enrollment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker.

23 Jun 2010

$Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors$

Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.

23 Jun 2010

Grant introduces new range of digital, analogue ultrasonic benchtop baths

Grant Instruments, a world-renowned supplier of scientific, life sciences and data acquisition products, has unveiled an advanced range of high quality, robust, fully-featured digital and analogue ultrasonic benchtop baths. The baths are designed to meet the growing need for reliable ultrasonic cleaning in laboratories and across pharmaceutical, medical, healthcare and industrial applications.

23 Jun 2010

BASF signs agreement to acquire Cognis for equity purchase price of euro 700 million

BASF SE has reached an agreement with Cognis Holding Luxembourg S.a r.l. controlled by Permira Funds, GS Capital Partners and SV Life Sciences to acquire the specialty chemicals company Cognis for an equity purchase price of euro 700 million. Including net financial debt and pension obligations, the enterprise value of the transaction is euro 3.1 billion. The acquisition is subject to clearance by the competent merger control authorities. Closing of the transaction is expected for November 2010 at the latest.

23 Jun 2010

IQ Therapeutics achieves 100% survival in rabbit model at 48 hours after inhalation anthrax infection

IQ Therapeutics B.V., Groningen, the Netherlands, announced this week that in collaboration with the University of Texas Medical Branch it has obtained outstanding results for the treatment of inhalation anthrax. In a rabbit model up to 100% survival could be achieved with extended time to treatment (48h post infection) with a combination of two specific monoclonal antibodies developed by IQ Therapeutics. This has significant potential for saving lives of infected people who have no immediate access to treatment.

23 Jun 2010

New research project to review accuracy of medical diagnoses

A new research project at the University of Leicester will review the accuracy of medical diagnoses. Evaluating diagnostic strategy is crucial to clinical practice as it helps maximise the efficacy of the treatments which are offered to patients. Many lives are affected every day by the diagnoses made by hospitals and medical doctors, and it is vital that diagnoses are accurate.

23 Jun 2010

Shift in balance between good and bad bacteria in gut could be a harbinger of colon cancer: Study

The human body contains more bacteria than it does cells. These bacterial communities can have a positive effect on our health, by training our immune systems and helping to metabolize the foods we eat. But they can also set us up to develop digestive disorders, skin diseases, and obesity.

23 Jun 2010

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

MAP Pharmaceuticals, Inc. announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial in a late breaker session at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California on Friday, June 25 from 3:30 to 4:00 pm PT. The presentation will show that the Company's investigational LEVADEX™ orally inhaled migraine therapy was effective irrespective of when it was administered during a migraine cycle.

23 Jun 2010

Company took measures to protect employees from H1N1 flu: National poll

In response to the H1N1 flu, most employees at U.S. businesses say their company took measures to protect them from illness, such as encouraging sick employees to stay home, according to a national poll of employees by researchers from the Harvard Opinion Research Program at Harvard School of Public Health.

23 Jun 2010

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Migraine sufferers who experienced abuse and neglect as children have a greater risk of cardiovascular (CV) disease including stroke and myocardial infarction (MI) among others, say scientists presenting data at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week.

23 Jun 2010

UK cancer survival rates increase at 3% each year

The number of people who are living with and beyond cancer (cancer survivors) has risen, according to new figures from the National Cancer Intelligence Network.

23 Jun 2010

START proteins could help treat cholesterol build-up in arteries: Report

A newly discovered group of proteins could help treat cholesterol build-up in arteries. This build-up leads to atherosclerosis or 'hardening of the arteries', and the resulting condition, coronary heart disease, kills an estimated 124,000 each year in England and Wales.

23 Jun 2010

Modern humans can achieve relatively high bite forces using less-powerful jaw muscles: Study

The robust jaws and formidable teeth of some of our ancestors and ape cousins may suggest that humans are wimps when it comes to producing a powerful bite: but a new study has found the opposite is true, with major implications for our understanding of diet in ancestral humans.

23 Jun 2010

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies and miRagen Therapeutics, Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today that they have formed a strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease.

23 Jun 2010

MDI raises $1.4M as part of follow-on to its $3.3M Series C financing round

Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.

23 Jun 2010

Spanish scientists propose human amniotic membrane as new tool for repairing damaged articular cartilage

Spanish scientists have proposed using human amniotic membrane as a new tool for repairing damaged human articular cartilage, which heals very poorly because of its low capacity for self-repair. Their research, published in the journal Cell and Tissue Banking, shows that the cellular density of the cartilage synthesised could be greater than that of the body's own natural cartilage.

23 Jun 2010

EUCODIS Bioscience launches high-performance beta-lactamase

EUCODIS Bioscience, a developer and manufacturer of customized enzymes today announced that it has launched a high-performance beta-lactamase designed to inactivate a broad range of beta-lactam antibiotics. EUCODIS Bioscience is marketing the product under the LacBuster(TM) brand.

23 Jun 2010

SOKO Fitness & Spa Group opens Daoli Fitness and Legend Spa Central Club in Harbin, China

SOKO Fitness & Spa Group, Inc., an operator of fitness centers, beauty salons and spas in Northeast China as well as suburban Beijing, today announced the opening of its two newest facilities, Daoli Fitness and Legend Spa Central Club. Both centers, which, as previously announced, have been engaged in pre-opening activities for several months, are located in the Long Dian Building in downtown Harbin, China, a centrally located building for SOKO's target upper-middle class clients.

23 Jun 2010

Rite Aid first-quarter revenues decrease 2.1% to $6.4 billion

Rite Aid Corporation today reported financial results for the first quarter ended May 29, 2010.

23 Jun 2010

TNI wins Stevie Award for Tradewinds magazine

Tahitian Noni International won a Stevie award for its Tradewinds magazine at the 2010 American Business Awards in New York City. Stevie Award winners were selected from more than 2,700 entries that had been submitted from organizations of all sizes, in all 50 states, and in virtually every industry in America.

23 Jun 2010

Medical News

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Grant introduces new range of digital, analogue ultrasonic benchtop baths

BASF signs agreement to acquire Cognis for equity purchase price of euro 700 million

IQ Therapeutics achieves 100% survival in rabbit model at 48 hours after inhalation anthrax infection

New research project to review accuracy of medical diagnoses

Shift in balance between good and bad bacteria in gut could be a harbinger of colon cancer: Study

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

Company took measures to protect employees from H1N1 flu: National poll

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

UK cancer survival rates increase at 3% each year

START proteins could help treat cholesterol build-up in arteries: Report

Modern humans can achieve relatively high bite forces using less-powerful jaw muscles: Study

Santaris Pharma, miRagen collaborate to develop microRNA-targeted medicines for cardiovascular disease

MDI raises $1.4M as part of follow-on to its $3.3M Series C financing round

Spanish scientists propose human amniotic membrane as new tool for repairing damaged articular cartilage

EUCODIS Bioscience launches high-performance beta-lactamase

SOKO Fitness & Spa Group opens Daoli Fitness and Legend Spa Central Club in Harbin, China

Rite Aid first-quarter revenues decrease 2.1% to $6.4 billion

TNI wins Stevie Award for Tradewinds magazine

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News